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during chemotherapy and 8-weekly after chemotherapy success-
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P24 SINGLE INSTITUTION EXPERIENCE OF ODONTOGENIC CYST
AND TUMOURS, AND TUMOUR-LIKE LESIONS OF THE JAW, IN
SOUTH KERALA – A 10-YEAR CLINICOPATHOLOGICAL SURVEY
P.S. Satheeshkumar *, A. Balan. Department of Oral Medicine and
Radiology, Government Dental College, Trivandrum, Kerala, India
Background: This study aimed to evaluate and compare the rel-
ative frequency, distribution, sites of presentation, and radiologi-
cal and histological variations of odontogenic cysts, tumours, and
tumour-like lesions in cases reported to the Government Dental
College, Trivandrum, India.
Methods: A retrospective analysis was done on 3222 biopsy
cases reported to the Department of Oral Medicine and Radiology
from January, 2000, to May, 2009. Biopsy records were also evalu-
ated from the Department of Oral Medicine and Department of
Oral Pathology and Microbiology.
Findings: Of 3222 biopsy cases reported, 1082 were diagnosed as
odontogenic cysts and tumours, and tumour-like lesionsof the jaw.
Of the 1082 cases, the highest frequencies were as follows: cyst of
inflammatory origin (periapical and radicular cyst; n = 589,
54.4%); ameloblastoma (n = 141, 13.03%); dentigerous cyst (n = 98,
9.05%); keratinising odontogenic tumour (n = 74, 6%); fibrous dys-
plasia (n = 25, 2%; females = 19, 75%; males = 6, 24%); dentigerous
cyst showing ameloblastoma transformation (n = 24, 2%); eruption
cyst (n = 55, 5%); osteoma (n = 22, 2%); central ossifying fibroma
(n = 20, 1.8%; females = 13, 65%; males = 7, 35%); odontome
(n = 16, 1.4%); adenomatoid odontogenic tumour (n = 6, 0.5%); cen-
tral giant-cell granuloma (n = 9, 0.8%); central odontogenic fibroma
(n = 6, 0.5%); cementoblastoma (n = 8, 0.8%); Pindborg tumour
(n = 5, 0.4%); and benign fibrous histiocytoma (n = 3, 0.2%). Rarer
conditions,which accounted for less than 0.2% of cases, were juve-
nile ossifying fibroma, ameloblastic fibrodontoma, chondrosar-
coma, central odontogenic myxoma, and plasma-cell myeloma.
Interpretation: The relative frequencies and sites of presenta-
tion of odontogenic cysts, tumours, and tumour-like lesions of
the jaw in different geographic backgrounds are essential for
early diagnosis and management of these potentially destructive
benign lesions.
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P25 IMPACT OF CONTRIBUTION BY ONCOLOGY PHARMACISTS
ON LYMPHOMAWARD ROUNDS
J. Chiang *, K. Tay, V. Shih, R. Quek, ST. Lim, M. Tao,
A. Chan. National Cancer Centre, Singapore
Background: In the oncology setting, specialist multidisciplin-
ary teams are often needed to ensure that patients receive the
best possible care and treatment. As drug experts, pharmacists
manage chemotherapy-related and supportive care issues. They
can also help to manage treatment costs and facilitate accurate
prescribing to maximise patient safety. Documentation of inter-
ventions done by pharmacists on ward rounds can be clinically
and educationally useful for improving prescribing safety and
pharmacy services. This study evaluated the impact of interven-
tions made by pharmacists on lymphoma ward rounds.
Methods: This was a cross-sectional analysis of interventions
made by pharmacists on the lymphoma service from 2009 to
2010, at Singapore General Hospital, where pharmacists from the
National Cancer Centre Singapore join lymphoma ward rounds 5
days a week. Interventions were documented in a database and
were given an impact rating by two independent reviewers – a lym-
phoma oncologist and an oncology pharmacist. Interventions
were classified into four impact levels and assessed as drug-
related, cost-related, or workflow issues. Spearmans correlation
test was used to test for agreement between the two reviewers.
Findings: A total of 295 interventions were made for 116
patients; 97% were accepted by oncologists. Most interventions
were related to antimicrobial dosing or usage (35%) and chemo-
therapy-related issues (29%). 23% of impact ratings were level 3
or 4. Ratings of interventions that helped to avoid or solve drug-
related problems and improve workflow were moderately concor-
dant between the two reviewers, in the areas of supportive care
(p = 0.544) and chemotherapy-related issues (p = 0.559). Overall,
the oncologist gave higher ratings for cost-saving interventions
and the pharmacist gave higher ratings for interventions that
help to avoid or resolve drug-related problems and improve
workflow.
Interpretation: Interventions by oncology pharmacists are well-
accepted onward rounds andhave a positive effect on patient care.
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P26 EXPRESSION OF MAGE-A3 AND ITS PROGNOSTIC VALUE IN
HEPATOCELLULAR CARCINOMA IN ASIAN PATIENTS
P. Lee a,*, T. Tanwandee b, A. Chotirosniramit c, D. DAgostino d,
J. Louahed d, A. Myo e, P. Therasse d. a National Taiwan University
Hospital, Taipei, Taiwan. b Siriraj Hospital, Mahidol University,
Bangkok, Thailand. c Maharajnakorn Chiang Mai Hospital,
ChiangMai, Thailand. d GlaxoSmithKline Biologicals, Rixensart,
Belgium. e GlaxoSmithKline Biologicals, Singapore
Background: The MAGE-A3 tumour-specific antigen is
expressed by many tumours, including hepatocellular carcinoma
(HCC), and is therefore an appropriate target for active immuno-
therapy. Here, we report results from a retrospective epidemiolog-
ical evaluation of MAGE-A3 gene expression in Asian patients
with pathologically proven HCC, and its prognostic value.
Methods: 200 samples were analysed from two centres in Thai-
land and one in Taiwan. Patient and tumour characteristics were
also collected. Formalin-fixed paraffin-embedded (FFPE) tumour
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tissue from surgical resection was tested for MAGE-A3 expres-
sion, by quantitative reverse-transcription polymerase chain
reaction (RT-PCR).
Findings: The overall rate of MAGE-A3 expression was 41% (37%
in Taiwan and 48% in Thailand, from 132 valid samples). MAGE-
A3 expression was lower in patients with HBV infection (33.3%)
than in HCV-infected patients (63.0%). No difference in MAGE-
A3 expression was noted for the following factors: age, gender,
liver cirrhosis, Child-Pugh class, chronic alcohol abuse, number
and size of (largest) tumours. No clinical effects on survival were
associated with MAGE-A3 expression in this HCC Asian popula-
tion. The hazard ratio (HR) for the disease-free interval for
MAGE-A3-positive versus MAGE-A3-negative patients was 1.06
(p = 0.82; HR adjusted for T stage, tumour number and size, cir-
rhosis, Child-Pugh score, and ECOG performance status was
1.40 [p = 0.29]). HRs for disease-free and overall survival were
1.03 (p = 0.91) and 0.97 (p = 0.94), respectively; adjusted HRs were
1.32 (p = 0.37) and 1.33 (p = 0.63). However, because of the small
number of patients, no subset analysis by stage or other variables
that affect disease-free and overall survival could be done.
Interpretation: MAGE-A3 can be assessed byRT-PCR on surgically
resected HCC. The overall expression rate is sufficient to consider
MAGE-A3 a target for active immunotherapy. The relatively higher
expression in HCV-infected patients has no explanation, so far.
Clinical evaluation of MAGE-A3 antigen-specific cancer immuno-
therapeutics in early HCC after resection is being discussed.
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P27 HIGH DOSE RATE BRACHYTHERAPY BOOST FOR RESIDUAL
MALIGNANT GLIOMA – CLINICAL RESULTS FROM A SINGLE
INSTITUTION
M. El-Naggar a, A. Fakhr b, H. Abdel-Baki a, A. Hassouna a,*, M. El
Sayed a. a Radiation Oncology Department, National Cancer Institute,
Cairo University, Cairo, Egypt. b Neurosurgery Department Faculty of
Medicine, Ain Shams University, Cairo, Egypt
Background: This study investigated the role of additional high
dose rate (HDR) brachytherapy boost, in patients with malignant
glioma who have residual lesions after conventional external-
beam radiotherapy (EBRT).
Methods: Thirty patients were included in this prospective,
non-randomised trial. After initial surgical intervention and EBRT
given as 60 Gy/30 fractions/6 weeks, patients with a post-radia-
tion residual lesion not more than 6 cm in maximum dimension
were selected: 16 patients in the experimental group and 14 in the
control group. Patients in the experimental group received a
brachytherapy boost dose of 24–25 Gy/5–6 fractions daily, using
a high dose rate Ir192 source.
Findings: Median follow-up was 1 year (range 0.4–7.5 years).
Median overall survival (OS) was 14 months for the boost group
and 11 months for the control group (p = 0.49). Median progres-
sion-free survival (PFS) was 10 months for the boost group and
8 months for control (p = 0.44). Acute and late toxicities were
low. Two patients developed limited CSF leakage, and one patient
reported severe pain.
Interpretation: Increasing the dose of radiation by additional
HDR brachytherapy boost prolonged the median OS by 3
months and PFS by 2 months, but the number of patients
was too small to reach statistical significance. The implant
was tolerable and the toxic effects of an additional HDR brach-
ytherapy boost were low, so this may be considered a safe
treatment option.
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P28 CHILDHOOD CANCER AND ITS IMPACT ON THE FAMILY—AN
ASIAN EXPERIENCE
L. Aung a,*, M.Y. Chan a, S.M. Sabai b, T.D. Khaing b, H.M.
Verkooijen c. a Paediatric Medicine and Subspecialties, KK Womens
and Childrens Hospital, Singapore. b Division of Pediatric Hematology-
Oncology, National University Hospital, Singapore. c National
University of Singapore, Singapore
Background: In Singapore, there is a lack of information on the
impact of childhood cancer on the family as a whole. We set out
to assess medical and non-medical costs of childhood cancer and
its psychosocial impact.
Methods: All patients diagnosed and treated at the Department
of Pediatrics, KK Womens and Childrens Hospital and National
University Hospital, Singapore, were eligible. Families were given
two self-administered questionnaires: one about the child and
family, and an impact-on-family scale. The total score was
obtained by summation of all scores, with a high score correlating
to high impact.
Findings: 79 parents were enrolled during the study period
(October, 2008–February, 2009). 48 of the children (61%) were
male. 57 (72%) of respondents were mothers and 51% had chil-
dren younger than 5 years. Most respondents were Chinese
(54%), followed by foreign (not from Singapore) patients at
33%. 44 (56%) had children with haematological malignancies,
and 38% had children with solid tumours. Reported financial
burden was higher than in US and Italian studies. No Malaysian
or Indian care-givers reported a high familial or social burden
(p = 0.05). All Malaysian and Indian care-givers reported low-to-
moderate psychological burden, whereas a large proportion of
Chinese reported a high burden (p = 0.03). Chinese reported the
highest levels of mastering (ie, coping strategies) within ethnic
subgroups (p = 0.001). Cronbachs alpha internal reliability was
0.64.
Interpretation: Overall, the burden of childhood cancer in Sin-
gapore is comparable to other countries. Factors associated
with high impact are ethnicity, employment status, and leave
status. Use of the impact-on-family scale needs further
research to see whether all domains are applicable to our local
culture.
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